PolyPid Revenue and Competitors

PolyPid®, a specialty pharmaceutical company, develops and manufactures products based on its PLEX? technology. So far, 70 patients have been treated in clinical trials with PolyPid?s anti-infection products demonstrating safety and efficacy. PolyPid is in the process of submitting its lead product for Phase-III trial in the US and EU. PLEX? is able to optimize drugs'? therapeutic performance and clinical outcomes. PLEX?-based protected drug reservoir is implanted directly into the body?s target area thus enabling prolonged delivery of drugs, over periods ranging from days to several months. PolyPid?s pipeline focuses on 3 products: D-PLEX? - intended for prevention and treatment of surgical infections caused by bacteria. Its effectiveness is currently being tested in patients undergoing open-heart surgery, with a view to preventing infections that may occur following surgery. The product is currently undergoing clinical studies at several medical centers. BonyPid®-1000 - designed to encourage bone healing and prevent bacterial infections in severe open fractures, usually caused by high-energy injuries. Tested in human studies, this product was shown to be safe and effective. Clinical trials demonstrated a decrease in amputations from 7% to 0%, 50% reduction in healing time and a drastically reduced infection rate from 25.5% to 0%. The product is undergoing a pivotal clinical trial prior to obtaining a European CE mark. BonyPid®-500 is designed to treat chronic infections in dental implants. The product is in a clinical trial in cooperation with Dentsply Sirona. Over the years PLEX? has shown a remarkable ability to encapsulate a wide variety of drugs, and has increased efficacy of two major US biotechnology companies? protein-based drugs. PolyPid is currently in the initial stages of establishing collaborative agreements with leading pharmaceutical companies. PolyPid?s technology was invented by Dr. Noam Emanuel, PolyPid?s founder and CTO.